特集 神経疾患治療の進歩2015年
免疫介在性中枢神経疾患の治療の進歩
2017 年 33 巻 4 号 p. 515-517
詳細
2017 年 33 巻 4 号 p. 515-517
Recent advances and new evidences related to treatment for multiple sclerosis (MS) were reviewed. In year of 2015, glatiramer acetate has been approved in Japan. New biological reagents have been developed in these several years, however, it seems very important to reconsider self injection agents such as interferon beta 1a/1b, or glatiramer acetate. They are still working well and very valuable.
From such point of view manuscripts especially regarding optimization of disease modifying therapy for MS were reviewed.
